Summary
The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ahlgren, J. D., Ellison, N. M., Gottlieb, R. J., Laluna, F., Lokich, J. J., Sinclair, P. R., Veno, W., Wampler, G. L., Yeung, K-Y, Alt, D. & Fryer, J. G. (1993). Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 11: 1957–1968.
Ball, D., Smith, J., Bishop, J., Olver, I., Davis, S., O’Brien, P., Bernshaw, D., Ryan, G. & Millward, M. (1997). A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small cell lung cancer. Br J Cancer 75: 690–697.
Barr, H., Krasner, N., Raouf, A. & Walker, R. J. (1990). Prospective randomised trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia. Gut 31: 252–258.
Brewster, A. E., Davidson, S. E., Makin, W. P., Stout, R. & Burt, P. A. (1995). Intraluminal brachytherapy using the high dose rate microselectron in the palliation of carcinoma of the oesophagus. Clin Oncol 7: 102–105.
Buroker, T. R., O’Connell, M. J., Weiand, H. S., Krook, J. E., Gerstner, J. B., Mailliard, J. A., Schaefer, P. L., Levitt, R., Kardinal, C. G. & Gesme, D. H. (1994). Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14–20.
Burris, H. & Storniolo, A. M. (1997). Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33: (suppl.1) S18–S22.
De Haes, JCJM, van Knippenberg, F. C. E. & Neijt, J. P. (1990). Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62: 1034–1038.
Glimelius, B., Hoffman, K., Sjoden, P. O., Jacobsson, G., Sellström, H., Enander, L-K, Linné, T. & Svensson, C. (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593–600.
Haie-Meder, C., Pellae-Cosset, B., Laplanche, A., Lagrange, J. L., Tuchais, C., Nogues, C. & Arriagada, R. (1993). Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiat Oncol 26: 111–116.
Hopwood, P. & Stephens, R. J., Machin, D. for the MRC Lung Cancer Working Party (1994). Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Quality Life Res 3: 339–352.
James, L. E., Gower, N. H., Rudd, R. M., Spiro, S. G., Harper, P. G., Trask, C. W., Partridge, M., Souhami, R. L. & Ruiz de Elvira, M-C (1996). A randomised trial of low-dose/ high-frequency chemotherapy as palliative treatment of poor-prognosis small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 73: 1563–1568.
Kurtz, J. M., Gelber, R., Brady, L. W., Carella, R. J. & Cooper, J. S. (1981). The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7: 891–895.
Leibel, S. A., Pajak, T. F., Massullo, V., Order, S. E., Komaki, R. U., Chang, C. H., Wasserman, T. H., Phillips, T. L., Lipshutz, J. & Durbin, L. M. (1987). A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys 13: 1057–1064.
Lewington, V. J., McEwan, A. J., Ackery, D. M., Bayly, R. J., Keeling, D. H., Macleod, P. M., Porter, A. T. & Zivanovic, M. A. (1991). A prospective randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced cancer metastatic to bone. Eur J Cancer 27: 954–958.
Maher, E. J., Hopwood, P., Girling, D. J., Macbeth, F. R. & Mansi, J. L. (1994). Measurement of outcome in palliative oncology. J Cancer Care 3: 94–102.
Marty, M., on behalf of the Granisetron Study Group (1992). A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. Eur J Cancer 28A: (suppl.1) S12–S16.
Medical Research Council Lung Cancer Working Party (1989a). Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small cell lung cancer. Respir Med 83: 51–58.
Medical Research Council Lung Cancer Working Party (1989b). Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer 59: 584–590.
Medical Research Council Lung Cancer Working Party (1991). Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 63: 265–270.
Medical Research Council Lung Cancer Working Party (1992). A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small cell lung cancer (NSCLC) and poor performance status. Br J Cancer 65: 934–941.
Medical Research Council Lung Cancer Working Party (1993). A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II. Quality of life. Br J Cancer 68: 1157–1166.
Medical Research Council Lung Cancer Working Party (1996). Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol 8: 167–175.
Medical Research Council Lung Cancer Working Party (1996). Randomized trial of four-drug versus less intensive two-drug chemotherapy in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis. Br J Cancer 73: 406–413.
Medical Research Council Lung Cancer Working Party (1996). Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre randomised trial. Lancet 348: 563–566.
Mohiuddin, M., Chen, E. & Ahmad, N. (1996). Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 14: 722–728.
Muers, M. F. & Round, C. E. (1993). Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation thoracic group. Thorax 48: 339–343.
Richards, M. A., Hopwood, P., Ramirez, A. J., Twelves, C. J., Ferguson, J., Gregory, W. M., Swindell, R., Scrivener, W., Miller, J., Howell, A. & Rubens, R. D. (1992). Doxorubicin and advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer 28A: 1023–1028.
Stephens, R. J., Girling, D. J. & Machin, D. (1994). Treatment-related deaths in small cell lung cancer: can patients at risk be identified?. Lung Cancer 11: 259–274.
Sur, R. K., Kochhar, R. & Singh, D. P. (1994). Oral sucralfate in acute radiation oesophagitis. Acta Oncol 33: 61–63.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M. L. & Murphy, K. C. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative endpoints. J Clin Oncol 14: 1756–1764.
Tong, D., Gillick, L. & Hendrickson, F. R. (1982). The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group. Cancer 50: 893–899.
Twelves, C. J., Dobbs, N. A., Lawrence, M. A., Ramirez, A. J., Summerhayes, M., Richards, M. A., Towlson, K. E. & Rubens, R. D. (1994). Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. Br J Cancer 69: 726–731.
Van Holten-Verzantvoort, A. T. M., Kroon, H. M., Bijvoet, O. L. M., Cleton, F. J., Beex, L. V. A. M., Blijham, G., Hermans, J., Neijt, J. P., Papapoulos, S. E., Sleeboom, H. P., Vermey, P. & Zwinderman, A. H. (1993). Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11: 491–498.
World Health Organization (1979). WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset publication no. 48. WHO: Geneva
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Stephens, R., Hopwood, P. & Girling, D. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 79, 538–544 (1999). https://doi.org/10.1038/sj.bjc.6690085
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690085
Keywords
This article is cited by
-
Palliative Surgery. What is it?
Hellenic Journal of Surgery (2018)
-
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)
BMC Cancer (2011)
-
Improvements of quality of life in patients with advanced non-small cell lung cancer treated with gefitinib
The Chinese-German Journal of Clinical Oncology (2009)
-
Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy
Quality of Life Research (2008)
-
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
British Journal of Cancer (2006)